

114TH CONGRESS  
2D SESSION

# H. R. 4713

To amend the market name of genetically altered salmon in the United States, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

MARCH 3, 2016

Mr. YOUNG of Alaska (for himself and Mr. DEFAZIO) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To amend the market name of genetically altered salmon in the United States, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Genetically Engineered  
5 Salmon Labeling Act”.

6 **SEC. 2. PURPOSES.**

7 It is the purpose of this Act to—

8 (1) ensure that consumers in the United States  
9 can make informed decisions when purchasing salm-  
10 on; and

1           (2) authorize an independent scientific review  
2 of—

3                   (A) the possible effects of genetically engi-  
4 neered salmon on wild salmon stocks; and

5                   (B) the Food and Drug Administration’s  
6 approval of genetically engineered salmon for  
7 human consumption.

8 **SEC. 3. MARKET NAME FOR GENETICALLY ENGINEERED**  
9 **SALMON.**

10       (a) IN GENERAL.—Notwithstanding any other provi-  
11 sion of law, for purposes of applying the Federal Food,  
12 Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), the ac-  
13 ceptable market name of any salmon that is genetically  
14 engineered shall include the words “Genetically Engi-  
15 neered” or “GE” prior to the existing acceptable market  
16 name.

17       (b) DEFINITION.—For purposes of this section, salm-  
18 on is genetically engineered if it has been modified by re-  
19 combinant DNA (rDNA) techniques, including the entire  
20 lineage of salmon that contain the rDNA modification.

21 **SEC. 4. THIRD-PARTY REVIEW OF CERTAIN SALMON AP-**  
22 **PROVAL.**

23       The Secretary of Health and Human Services shall  
24 ensure that an independent scientific organization con-  
25 ducts a review of the environmental assessment that was

1 carried out by the Food and Drug Administration in sup-  
2 port of an approval of a new animal drug application re-  
3 lated to AquAdvantage Salmon, dated November 12,  
4 2015.

○